- Citado por SciELO
- Similares em SciELO
versão On-line ISSN 1680-5348versão impressa ISSN 1020-4989
Rev Panam Salud Publica vol.32 no.1 Washington Jul. 2012
ORIGINAL RESEARCH INVESTIGACIÓN ORIGINAL
Prueba de tuberculosis en poblaciones con riesgo alto de VIH en Tijuana, Baja California, México
Michele G. VelasquezI; Rafael Laniado-LaborinII; Timothy C. RodwellI; Paris CerecerIII; Remedios LozadaIV; Jazmine Cuevas-MotaI; Jose Luis BurgosI; Richard S. GarfeinI,*
IUniversity of California, San Diego, School of Medicine, San Diego, California, United States of America
IIUniversidad Autónoma de Baja California, Tijuana, Baja California, México
IIIInstituto de Servicios de Salud Pública, Baja California, México
IVPatronato Pro-COMUSIDA, Tijuana, Baja California, México
OBJECTIVE: To assess the prevalence of prior tuberculin skin testing (TST) among populations at risk for HIV infection in Tijuana, Mexico, and to identify factors associated with TST.
METHODS: Sex workers, injection drug users, noninjecting drug users, and homeless persons > 18 years old were recruited by using targeted sampling for risk assessment interviews and serologic testing for HIV and Mycobacterium tuberculosis infection. Univariate and multivariate logistic regression were used to identify correlates of self-reported TST history.
RESULTS: Of 502 participants, 38.0% reported prior TST, which was associated with previous incarceration in the United States of America [odds ratio (OR) = 13.38; 95% confidence interval (CI) = 7.37-24.33] and injection drug use (OR = 1.99; 95% CI = 1.27- 3.11). Positive results on serologic tests for M. tuberculosis infection (57%) and HIV (4.2%) were not associated with a prior TST.
CONCLUSIONS: A history of TST was lower in HIV-positive participants even though TST is indicated for persons with HIV in Mexico. Fewer than half the individuals at high risk for HIV in this study had a history of TST; however, TST was fairly common among those individuals with a prior history of incarceration. Increased tuberculosis screening is needed for populations at risk of contracting HIV in Tijuana, particularly those outside of criminal justice settings.
Key words: Tuberculosis; tuberculin test; drug users; HIV; Mexico.
OBJETIVO: Evaluar la prevalencia de la prueba de la tuberculina previa, e identificar los factores asociados con ella, en poblaciones con riesgo de infección por el VIH en Tijuana, México.
MÉTODOS: Se reclutó a profesionales del sexo, consumidores de drogas inyectables y no inyectables y personas sin hogar > 18 años de edad mediante un muestreo dirigido a fin de efectuar entrevistas para evaluar el riesgo y pruebas serológicas para la infección por el VIH y Mycobacterium tuberculosis. Para identificar la correlación de los antecedentes de la prueba de la tuberculina proporcionados por el propio individuo se usó regresión logística de una sola variable y con múltiples variables.
RESULTADOS: De 502 participantes, 38,0% informaron una prueba de la tuberculina previa, que se asoció con encarcelamiento anterior en los Estados Unidos de América (razón de posibilidades [OR] = 13,38; intervalo de confianza de 95% [IC] = 7,37-24,33) y consumo de drogas inyectables (OR = 1,99; IC de 95% = 1,27-3,11). Los resultados positivos en las pruebas serológicas para la infección con M. tuberculosis (57%) y VIH (4,2%) no se asociaron con una prueba de la tuberculina previa.
CONCLUSIONES: Los antecedentes de una prueba de la tuberculina fueron menores en los participantes seropositivos para el VIH, a pesar de que en México esta prueba está indicada en las personas con VIH. En este estudio menos de la mitad de los individuos con alto riesgo de VIH tenían antecedentes de la prueba de la tuberculina; sin embargo, esta fue bastante frecuente en los individuos con antecedentes de encarcelamiento. En las poblaciones en riesgo de contraer el VIH en Tijuana se requiere un mayor tamizaje de tuberculosis, en particular en aquellas no relacionadas con el ambiente de la justicia penal.
Palabras clave: Tuberculosis; prueba de tuberculina; consumidores de drogas; VIH; México.
In 2007, a study was conducted to identify the prevalence and correlates of Mycobacterium tuberculosis (MTB) and HIV infection among marginalized populations with high risk for HIV infection in Tijuana, Baja California, Mexico (1). Test results using the QuantiFERON TB Gold in-Tube® (QFT) interferon gamma release assay indicated that 57% of participants overall had latent tuberculosis infection (LTBI). Although the prevalence of HIV was only 4.2%, the selfreported risk behaviors associated with HIV infection were highly prevalent, suggesting that these groups were at risk for HIV/tuberculosis (TB) coinfection.
Individuals with LTBI and HIV coinfection have an annual risk of progressing to active TB disease of 10%, compared with individuals with intact immune systems who have only a 10% lifetime risk of reactivation (2). While an estimated one-third of HIV-infected individuals globally are coinfected with TB, and TB is the leading cause of death among persons with AIDS, only 1% of persons living with HIV/AIDS worldwide have been screened for TB (3). It is therefore critical that individuals infected or at risk for infection with HIV be tested for TB early and often.
A study in the four northern Mexico border states found that TB rates for Mexican-born persons were 5.0 times as high as those for persons born in the United States of America (4). The state of Baja California, Mexico, situated across the border from California, United States, has a TB disease incidence rate of 57.3 per 100 000 population (the highest incidence of pulmonary TB in Mexico) (5) and has a policy of screening HIV-infected individuals for LTBI. It is unknown, however, whether individuals with HIV infection or those at high risk for HIV infection have been screened for TB. Therefore, the prevalence of prior tuberculin skin testing (TST) among populations at risk for HIV infection in Tijuana, Mexico was assessed and factors associated with prior TST were identified.
MATERIALS AND METHODS
The aims of the parent study were to measure the prevalence of LTBI and active TB disease among these groups and to identify correlates of infection. This cross-sectional study collected data from April to July 2007 among individuals recruited through targeted sampling in Tijuana. Eligibility included age > 18 years, willingness to provide signed informed consent, no plans to leave Tijuana in the next 30 days, and reporting any of the following in the six months before recruitment: illicit drug use (other than marijuana), injection drug use, receiving money or goods in exchange for sex, and homelessness (includes unstable housing defined as living mainly in a rented hotel room, migrant work camp, or medical/drug treatment facility).
Participants were recruited through targeted sampling using street-based outreach, word of mouth, and advertising (1). A recreational vehicle converted into a mobile health clinic was used to provide harm reduction education and basic health care services for high-risk populations and was used to access potential participants. All interviews were conducted at a storefront in a high-druguse neighborhood in Tijuana. The study protocol was approved by the University of California, San Diego, Institutional Review Board (IRB) and the Tijuana General Hospital Ethics Board. Further approval for this analysis was obtained from the San Diego State University IRB.
Participant risk assessment data were collected during one-on-one private interviews. Interviews were conducted in Spanish by local staff highly familiar with the target population and experienced in gaining participants' trust so they felt comfortable providing honest responses to sensitive questions. The interviews assessed sociodemographics, risk factors for MTB and HIV infection, TB knowledge and exposure history, prior TB testing, and presence of TB-related symptoms. The survey instrument was developed in English, translated into Spanish, and then backtranslated into English to verify accuracy and meaning. After the interview, participants received pretest counseling and venipuncture for HIV and MTB testing. Monetary reimbursement equivalent to US$20 was given to participants for time and transportation.
Median age (36 years) was used to create a dichotomous age variable. Since very few participants identified as transgender, the male-to-female (MTF) group was categorized as female (No. = 10) and the female-to-male (FTM) group was categorized as male (No. = 3) for the purposes of this study. Lifetime measures included ever crossing the border into the United States; ever incarcerated (defined as having been detained in a jail, prison, or other adult detention center); country where incarceration occurred; and had health insurance in the past 6 months.
Self-reported lifetime history of sexually transmitted infections and positive TB results included only those diagnosed by a medical professional. TB knowledge was assessed using six TB knowledge questions:
Can people have TB in their body that is sleeping and not an active form of disease?
Does sharing dishes, bottles, or a toothbrush with someone who has TB increase a person's chance of getting TB?
Can TB be spread from person to person through the air?
Can TB be cured by taking medicines?
Does receiving a BCG [bacillus Calmette-Guérin] vaccination protect you from TB for life?
If someone has TB, would you think that they also have HIV?
Participants were given one point for each correct answer and their combined scores, ranging from 0 to 6, were analyzed as a continuous variable. TST history was assessed by asking participants if they had ever had a skin test for TB.
TB infection was detected using the QuantiFERON TB Gold in-Tube® assay ([QFT] Cellestis, Ltd. Carnegie, Australia), an in vitro test that detects infections but does not differentiate LTBI from active TB disease (6). The detection of antibodies against HIV was obtained by using the Determine Rapid HIV Antibody Test (Abbot Laboratories, Boston, Massachusetts, United States). Positive results were confirmed by enzymelinked immunosorbent assay and immunofluorescent antibody assay at the San Diego County Public Health Laboratory. Participants with > 1 acid fast bacillus-positive sputum smear or chest radiography readings consistent with TB diagnosis were determined likely to have active TB and were referred to the central public health clinic (Instituto de Servicios de Salud Pública del Estado de Baja California) for clinical confirmation and treatment through the national TB program (1). All participants were given an appointment to receive the results of their HIV and QFT tests, posttest counseling, and referrals for treatment as described elsewhere (1).
Variables were analyzed using means or medians for continuous measures and frequencies and percentages for categorical variables. The dependent variable for this analysis was self-reported lifetime history of TST (yes or no). Associations between independent variables and TST history were examined by using chi-square tests for categorical variables and t-tests or Wilcoxon rank-sum tests for continuous variables depending on whether the data were normally distributed. Logistic regression was used to assess the univariate and multivariate odds ratios (ORs) and 95% confidence intervals (CIs) of selected factors with TST history. All variables found to be significant (P < 0.10) in the univariate analysis were considered for inclusion in multivariate analysis. Backward stepwise regression was performed to produce initial models. Factors that were independently associated with TST (P < 0.05) in multivariate analysis were considered statistically significant and maintained in the final model. The Hosmer-Lemeshow goodness-of-fit statistic and 95th percentile CIs were analyzed to determine the fit of the final model. Collinearity among independent variables was assessed by examining tolerance values. Analyses were performed with SPSS statistical software, version 16.0 (SPSS Inc., Chicago, Illinois, United States).
Only one participant answered "do not know" to the question on prior history of TST and was excluded; therefore, 502 participants were included in this analysis. Sixty-one percent of the sample were male (No. = 307), almost two-thirds were under 36 years old (No. = 264), and most (96.8%) were born in Mexico (No. = 487); however, 72.2% had ever crossed the border into the United States (No. = 363). Education was low, with only 10.9% completing more than a secondary school education (No. = 55), and 67.2% had ever been in jail (No. = 338). Thirty-eight percent of the sample reported ever receiving TST (No. = 191) and of those who had a previous skin test, 15.7% had tested positive (No. = 30). Past history of LTBI diagnosis was reported by 7.3% of participants (No. = 35). Of those with prior TST, 1.0% were HIV positive (No. = 2).
Serologic testing revealed that 56.9% were positive for TB infection by QFT assay (interferon gamma release assay) (No. = 286) and 4.2% were HIV positive (No. = 21). Of those who had reported having a previous TST, 58.1% (No. = 111) tested QFT positive (1).
Self-reported treatment for active and latent TB infection was also investigated. Of the 38.0% of the study population with a history of TST, 14.1% had been diagnosed with active TB by a medical professional (No. = 27). Most of those (81.5%) who had a previous active TB diagnosis were diagnosed in prison (No. = 22), and 88.9% had begun treatment (No. = 24). Half of those who had been treated (45.8%) had stopped treatment early (No. = 11). Of the 38.0% who had a prior TST, 16.8% had been previously diagnosed by a medical professional as having latent TB (No. = 32). The majority (78.1%) had been diagnosed in prison (No. = 25), and 93.8% had received treatment (No. = 30). Only 13.2% had stopped LTBI treatment early (No. = 4), defined as taking medications for less than 6 months.
Univariate analyses of factors associated with TST
The odds of a previous TST were greater among those older than 36 years (56.0% versus 42.1%), those who had crossed into the United States (86.9% versus 63.0%), those who had injected drugs in the past 6 months (59.2% versus 37.9%), and those who had ever been incarcerated (72.8% versus 19.0%) (all P < 0.05) (Table 1). The odds of a prior TST were lower among those who reported sex work (17.3% versus 26.4%), those who tested HIV positive (0.01% versus 6.1%), and those who had ever been diagnosed with a sexually transmitted infection (0.52% versus 8.4%) (all P < 0.05). No other factors investigated were associated with TST.
Multivariate logistic regression model of factors associated with TST
Considering all variables were associated with P < 0.10 in univariate analysis, the following remained statistically significant at a level of 0.05 in multivariate analysis. The odds of previous TST were 13.4 times greater among those who were incarcerated in the United States (95% CI = 7.37-24.33). The odds of a previous TST were higher among those who injected drugs in the past 6 months (OR = 1.99, 95% CI = 1.27-3.11) (Table 2). After adjusting for these variables, age, gender, and travel to the United States were no longer significant. The Hosmer- Lemeshow goodness-of-fit test statistic was 0.250 (> 0.05), indicating that the logistic model was a good fit.
This study showed that among individuals at high risk for HIV and MTB infection, the odds of having been screened for TB were higher among those with a history of incarceration, especially in jails in the United States. These results align with the U.S. Marshals Service TB policy, which requires that prisoners be tested as soon as conveniently possible after intake at a jail or detention center (7). Previous studies have used jail as a forum to measure the spread and control of TB (8-10). These data suggest that prisoners are accessing care and screening more often than those who are not incarcerated. While jails and detention centers are a potential avenue for providing care, it is clear that more options for testing should be available to high-risk individuals who are not incarcerated.
This study also found that after adjusting for incarceration, the odds of a previous TST were greater among injection drug users (IDUs), suggesting that IDUs might be targeted for TB screening more often than those who do not inject drugs. It is possible that IDUs are tested in drug treatment programs. However, participants were not asked where they received TST or about a lifetime history of drug treatment. This differs from previous studies, which have described IDUs as having difficulty completing medical evaluations (11-13). Nonetheless, it is a positive finding given that IDUs are one of the highest risk groups for HIV infection in Mexico and that the prevalence of HIV among IDUs in Tijuana is increasing (14). Further research should be conducted on IDUs and access to care to understand if it is a potential area for leveraging health promotion with regard to TB screening and treatment.
Serologic test results for MTB infection (i.e., QFT) and HIV were included in the analysis to determine whether those who had a prior TST were more or less likely to be QFT positive or HIV positive. No association was found between QFT results and prior TST in univariate and multivariate analyses.
Of concern was the finding that the odds of a previous TST were lower in HIV-positive participants than in HIVnegative participants even though TST is indicated for persons with HIV in Mexico. This finding was consistent, however, with prior reports showing that only 1% of individuals with HIV/AIDS worldwide have a history of TST (3). Further efforts are needed in Tijuana to ensure that all persons with HIV are screened for active TB disease and LTBI.
Self-reported treatment for active and latent TB infection was examined and it was found that of those who had reported prior TST and diagnosis with latent or active TB infection, the majority had been diagnosed in prison. Almost half of those who had been diagnosed with active TB reported stopping treatment early. This is consistent with a previous study also conducted in Tijuana in a population at high risk for HIV, which found a little over half of the population was able to finish treatment (15).
Certain limitations should be considered in interpreting the study findings. The data collected for this study are cross-sectional, which limits our ability to determine the temporal relation between TST and the associated factors; therefore, none of the reported associations should be considered causal. Additionally, because the parent study was not designed to identify correlates of TST, some desired variables, such as place of testing and reasons for testing, were not assessed. Recall of lifetime factors could have led to misclassification of participants by TST status. However, since TST history was not an eligibility criterion for the study, such misclassification would likely be nondifferential; thus, bias would result in a reduction in the observed ORs toward the null and strengthens our confidence in the results.
In a population with a high prevalence of MTB infection and high risk for HIV infection, an increase in HIV infection could fuel an outbreak of active TB disease. It is therefore important for persons with, or at risk for, HIV infection to know their TB status as treatment for LTBI is available. Since TST is known to crossreact with the bacillus Calmette-Guérin (BCG) vaccination (which is widely used in Mexico) (16), the use of TST was expected to be low in Tijuana. However, TST use was found to be fairly common but disproportionate and highly associated with a history of incarceration in the United States. Nonetheless, these findings indicate the need to increase TB screening among populations at risk for HIV in Tijuana, particularly those outside of criminal justice settings. Further research should be conducted to identify innovative ways to provide TB testing for populations at risk for HIV and TB coinfection in Mexico. One such innovation could include the use of interferon gamma release assays, which do not cross-react with the BCG vaccination (16), for diagnosing MTB infection in Mexico.
Acknowledgments. This work was supported by the U.S. Agency for International Development (grant GSM- 025). T.C.R. received financial support from the California HIV/AIDS Research Program at the University of California (fellowship CF07-SD-302) and the National Institutes of Health (grants T32 DA023356 and K01AI083784-01). J.L.B. was supported by the National Institute of Allergy and Infectious Diseases (grant T32-AI07384) and the National Institute of Drug Abuse (diversity supplement DA023877-S2). The authors gratefully acknowledge the contributions of study participants and staff-Pro-COMUSIDA for support with data collection and Instituto de Servicios de Salud del Estado de Baja California for contributing to this research. The authors acknowledge Andrea Mantsios, Pricillina Orosovitch, and Alicia Vera for their expert management of the Tijuana study site. The authors also acknowledge Donald Slymen and Robert Seidman for their skilled advice on the analysis and early drafts of the paper.
1. Garfein RS, Laniado-Laborin R, Rodwell TC, Lozada R, Deiss R, Burgos JL, et al. Latent tuberculosis among persons at risk for infection with HIV, Tijuana, Mexico. Emerg Infect Dis. 2010;16(5):757-63. [ Links ]
2. Corbett EL, De Cock KM. Tuberculosis in the HIV-positive patient. Br J Hosp Med. 1996;56(5):200-4. [ Links ]
3. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2010. Data from 2006 WHO/HTM/TB/2009.393. Geneva: WHO; 2010. [ Links ]
4. Schneider E, Laserson KF, Wells CD, Moore M. Tuberculosis along the United States-Mexico border, 1993-2001. Rev Panam Salud Publica. 2004;16(1):23-34. [ Links ]
5. Secretaría de Salud. Mexico 2004. Información para la rendición de cuentas 2005. Available from: http://www.salud.gob.mx/uni dades/evaluacion/saludmex2004/sm2004. pdf Accessed 2 December 2009. [ Links ]
6. Cellestis. QuantiFERON Gold in-Tube®. Valencia, California: Cellestis; 2008. Available from: http://www.cellestis.com/IRM/Company/ShowPage.aspx?CPID=1414 Accessed 9 January 2009. [ Links ]
7. United States Marshals Service's Prisoner Medical Care. Washington, D.C.: U.S. Department of Justice; 2004. Available from: http://www.justice.gov/oig/reports/USMS/a0414/final.pdf Accessed 2 December 2009. [ Links ]
8. Rutz HJ, Bur S, Lobato MN, Baucom S, Bohle E, Baruch NG. Tuberculosis control in a large urban jail: discordance between policy and reality. J Public Health Manag Practice. 2008;14(5):442-7. [ Links ]
9. Andre M, Ijaz, K, Tillinghast JD, Krebs VE, Diem LA, Metchock B, et al. Transmission network analysis to complement routine tuberculosis contact investigations. Am J Public Health. 2007;97(3):470-7. [ Links ]
10. Abrahão RM, Noqueira PA, Malucelli MI. Tuberculosis in county jail prisoners in the western sector of the city of São Paulo, Brazil. Int J Tuberc Lung Dis. 2006;10(2):203-8. [ Links ]
11. Rusen ID, Yuan L, Millson ME. Prevalence of Mycobacterium tuberculosis infection among injection drug users in Toronto. CMAJ. 1999;160(6):799-802. [ Links ]
12. Brassard P, Bruneau J, Schwartzman K, Sénécal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis. 2004;8(8):988-93. [ Links ]
13. Pilote L, Tulsky JP, Zolopa AR, Hahn JA, Schecter GF, Moss AR. Tuberculosis prophylaxis in the homeless: a trial to improve adherence to referral. Arch Intern Med. 1996;156(2):161-5. [ Links ]
14. Strathdee SA, Magis-Rodriguez C. Mexico's evolving HIV epidemic. JAMA. 2008;300(5):571-3. [ Links ]
15. Deiss R, Garfein RS, Lozada R, Burgos JL, Brouwer KC, Moser KS, et al. Influences of cross-border mobility on tuberculosis diagnoses and treatment interruption among injection drug users in Tijuana, Mexico. Am J Public Health. 2009;99(8):1491-5. [ Links ]
16. Higuchi K. QFT test and TST test in diagnosis of TB infection. Nihon Rinsho. 2011;69(8):1378-83. [ Links ]
Manuscript received on 29 August 2011.
Revised version accepted for publication on 29 February 2012.